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AbstrAct
Glioblastoma multiforme (GBM) is the most common malignant brain tumor 
in adults. The current standard of care includes surgery followed by radiotherapy 
(RT) and chemotherapy with temozolomide (TMZ). Treatment often fails due to the 
radiation resistance and intrinsic or acquired TMZ resistance of a small percentage of 
cells with stem cell-like behavior (CSC). The NOTCH signaling pathway is expressed 
and active in human glioblastoma and NOTCH inhibitors attenuate tumor growth 
in vivo in xenograft models. Here we show using an image guided micro-CT and 
precision radiotherapy platform that a combination of the clinically approved NOTCH/
γ-secretase inhibitor (GSI) RO4929097 with standard of care (TMZ + RT) reduces 
tumor growth and prolongs survival compared to dual combinations. We show that 
GSI in combination with RT and TMZ attenuates proliferation, decreases 3D spheroid 
growth and results into a marked reduction in clonogenic survival in primary and 
established glioma cell lines. We found that the glioma stem cell marker CD133, SOX2 
and Nestin were reduced following combination treatments and NOTCH inhibitors 
albeit in a different manner. These findings indicate that NOTCH inhibition combined 
with standard of care treatment has an anti-glioma stem cell effect which provides an 
improved survival benefit for GBM and encourages further translational and clinical 
studies.
IntroductIon
Glioblastoma multiforme (GBM) is the most 
common malignant brain tumor in adults. Multimodal 
treatment of surgery followed by radiotherapy (RT) and 
chemotherapy using temozolomide (TMZ) extends the 
two-year median survival rate of patients from 10% 
with radiotherapy alone to 27% when combined with 
temozolomide [1]. However, approximately 50% of brain 
tumors [2–3] as well as the large majority of the recurrent 
tumors [4–5] are resistant to TMZ. Tumors often respond 
to radiotherapy, but recurrence is almost inevitable due 
to the emergence of radiation resistant cells. Treatment 
failure leads to a high mortality in GBM patients and 
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therefore, there is a great need for novel treatments that 
improve clinical management and disease outcome. 
In GBM, a subpopulation of radiation resistant 
tumor cells expressing neural stem cell markers such as 
CD133 with high proliferative and self-renewal capacity 
have been shown to contribute to tumor recurrence. 
These cells are often referred to as glioma stem cells 
[6–7]. Chemotherapeutic drugs including TMZ as well 
as radiation therapy were shown to predominantly target 
the CD133-negative population and as such enrich the 
CD133-positive population [7–8]. Thus, conventional 
chemoradiotherapy appears to effectively remove the bulk 
of tumor cells, while leaving many GBM stem cells alive, 
driving treatment resistance and tumor relapse. Altogether, 
it appears that eradication of these cells is needed to 
augment treatment efficacy and outcome. 
NOTCH ligands, receptors and target genes are 
frequently over-expressed in glioma tissues or cell 
lines [9–11] and the NOTCH pathway is important 
in maintenance of glioma stem cells [12]. γ-secretase 
inhibitors (GSI) effectively inhibit the NOTCH pathway 
in basic and pre-clinical research as well as clinical trials 
[13–14]. Inhibition of NOTCH signaling in glioma stem 
cells has been shown to impair the tumorigenic capacity 
of these cells and enhance their radiation and chemo-
sensitivity [15–18]. Importantly, NOTCH inhibition has 
also been linked to TMZ-resistance through the EGF 
containing fibulin-like extracellular matrix protein 1 
(EFEMP1) [19]. While these results are promising, the 
therapeutic potential of NOTCH inhibition still has to be 
demonstrated in models that are more representative of the 
clinical situation to fully assess their benefit in the context 
of standard of care treatment. 
In this study, we investigated for the first time 
the efficacy of a clinically approved NOTCH inhibitor 
(RO4929097) in tumor control when combined with RT-
only, TMZ -only and RT + TMZ treatment groups in a 2D 
and 3D spheroid model in vitro as well as in an orthotopic 
GBM mouse model. Combining GSI with either RT or 
TMZ significantly reduced the glioma spheroid growth 
and tumor progression and prolonged survival when 
compared with single treatments. This effect was most 
pronounced with the triple combination (GSI + RT + 
TMZ) and resulted in an increased tumor growth delay 
when compared with dual treatments. The expression 
of glioma stem cell marker CD133 was reduced after 
single or combined treatments with NOTCH inhibitors, 
whereas the triple combination also decreased SOX2 
and Nestin expression. Our results suggest that one of 
the underlying mechanisms for the enhanced efficacy of 
NOTCH blockade when combined with chemotherapy and 
radiation is a reduced clonogenic survival of glioma stem 
/progenitor cells. 
results
notcH pathway is active in GbM cells
To address if the NOTCH pathway was active in our 
glioma cell lines, we analyzed the gene expression profile 
of NOTCH receptors (NOTCH1-4), ligands (DLL 1,3,4 
JAG 1,2) and target (HES1, HEY1,2) genes. Differential 
expression of NOTCH pathway components was 
confirmed by qPCR in both U87 and primary E2 GBM 
cells (Figure 1A and 1C). Blocking NOTCH/γ-secretase 
using 5- or 10 uM of GSI (RO4929097) significantly 
reduced the expression of the NOTCH target genes HES1 
and HEY2 in U87 cells (Figure 1B) and HEY1 and HEY2 
in E2 cells (Figure 1D). HEY2 expression in E2 cells 
was only significantly reduced using 10 uM GSI, while 
no significant change was observed for HES1 expression 
(Figure 1D). HEY1 expression in U87 cells was not 
significantly reduced upon GSI treatment most likely due 
to the low HEY1 expression in U87 cells (Figure 1A).
notcH inhibition in combination with rt and 
tMZ attenuates proliferation and clonogenic 
survival in vitro
Next, we investigated the effect of NOTCH 
inhibition as mono-therapy or in combination with 
RT and TMZ on proliferation of U87 and E2 cells in 
2D monolayer cultures. In U87 cells, treatment with 
GSI, TMZ and TMZ + GSI did not affect proliferation 
significantly compared with the vehicle control (DMSO). 
Upon RT (4Gy) treatment, GSI-only, TMZ-only and TMZ 
+ GSI significantly reduced proliferation compared to 
vehicle control (p < 0.001, in all cases) (Figure 2A). In E2 
primary glioma cells treatment with GSI and TMZ alone 
did not affect proliferation significantly compared with the 
vehicle control (DMSO), while TMZ + GSI did (p < 0.05). 
Upon RT (4Gy) treatment, GSI significantly reduced 
proliferation compared to vehicle control (P < 0.01). 
Similarly, after RT treatment TMZ + GSI significantly 
reduced proliferation compared to vehicle control, TMZ 
and GSI treatments (p < 0.0001, p < 0.001 and p < 0.0001, 
respectively) (Figure 2B). 
Next, we examined the effect of combination 
treatments on clonogenic survival. In U87 cells, upon 
RT, GSI and TMZ did not affect the clonogenic survival 
compared with the vehicle control (DMSO), however 
the survival fraction was markedly reduced in the GSI 
+ TMZ treatment group at 2,4, and 6 Gy and a highly 
significant synergistic effect was observed (p < 0.0001) 
(Figure 2C). The mean inactivation dose (50% reduction 
in clonogenicity) for GSI + TMZ was 2.28 Gy and for 
control + TMZ 3.2 Gy, respectively. In E2 cells, RT, GSI 
and TMZ reduced the clonogenic survival compared with 
the vehicle control (DMSO) (p = 0.047 and p = 0.02, 
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respectively). Clonogenicity was further reduced in GSI + 
TMZ irradiated cells and this effect was synergistic with 
2 Gy irradiation (p = 0.0002) (Figure 2D) (Supplementary 
Figure 1).
We then investigated the effects of single and 
combined treatment in a three-dimensional spheroid assay 
of U87 GBM cells. Four days post-seeding, U87 spheroids 
were irradiated with a single dose RT (4 Gy) and then 
treated with TMZ (5 uM) and GSI (10 uM) (Figure 3A). 
In the absence of radiation (0 Gy), NOTCH inhibitor 
alone did not affect the spheroid growth compared with 
the vehicle control, however when combined with TMZ 
an enhanced effect was observed (p = 0.01) (Figure 3B). 
RT treatment significantly delayed spheroid growth 
(p = 0.005), which was further enhanced upon treatment 
with GSI compared to non-RT treated cells (p = 0.007) 
(Figure 3C). Finally, GSI combined with TMZ and single 
dose RT treatment (GSI + TMZ + RT) resulted in the most 
pronounced growth delay when compared with either 
treatment combination including the standard of care, 
TMZ + RT, (p = 0.02) (Figure 3D–3E). Representative 
images of spheroids in each treatment group at different 
time points post-treatment are shown (Supplementary 
Figure 2). For E2 cells, spheroids formed but were not 
able to grow consistently over time in agarose-coated 
plates (not shown). Therefore, we performed the 3D 
spheroid assay in another primary GBM cell line; G7 
(Supplementary Figure 3). In the absence of radiation 
(0Gy), NOTCH inhibitor alone did not affect the spheroid 
growth compared with the vehicle control, however 
when combined with TMZ a significant growth delay 
was observed (p = 0.02) (Supplementary Figure 3A). 
RT treatment also significantly delayed spheroid growth 
(p = 0.01), which was further enhanced upon treatment 
Figure 1: notcH signaling in GbM cell lines. (A and c) mRNA expression of the NOTCH receptors, ligands and target genes in 
GBM cell lines were determined by qRT-PCR in U87MG-Luc2 and E2 cells. (b and d) mRNA expression of NOTCH target genes (HES1, 
HEY1 and HEY2) reduced after treatment with different concentrations of clinically available GSI RO4929097 as determined by qRT-
PCR. Values were normalized to Actin. Error bars indicate SEM. Asterisk indicates significance (*P < 0.05, **P < 0.01, ns: not significant).
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with GSI compared to control (p = 0.03) (Supplementary 
Figure 3B). Finally, the most pronounced growth delay 
was observed in spheroids treated with GSI + RT + TMZ 
(p = 0.03) (Supplementary Figure 3C–3D). There was no 
significant interaction between GSI and RT + TMZ (two-
way ANOVA; P > 0.05), the effect of the combination 
therapy in G7 was additive.
notcH inhibition combined with standard 
of care treatment reduces tumor growth and 
prolongs survival of intracranial glioblastoma  
in vivo
Next, we assessed the effects of NOTCH inhibition 
in combination with TMZ and single dose RT on the 
survival of mice with U87 intracranial glioblastoma. We 
previously determined that single dose RT of 8 Gy results 
in a significant but modest tumor growth delay compared 
to tumors that did not receive any irradiation [20], thereby 
providing a window of opportunity where the combined 
effects of RT and TMZ could be measured. One week post-
implantation, mice were imaged with BioLuminescence 
Imaging (BLI) 3 × /week. Contrast-enhanced micro-CT 
was also used to monitor tumor growth periodically as 
reported previously [20]. Upon confirmation of tumor 
growth by either BLI or micro-CT, mice were randomized 
into eight different treatment arms. These mice were 
treated with GSI/vehicle, TMZ/vehicle as well as radiation 
(Figure 5A) using a dedicated small animal irradiator and 
associated treatment planning software (SmART-Plan) 
to create irradiation plans to deliver a conformal dose of 
8 Gy to the tumor with minimal normal tissue exposure. 
An example of the parallel-opposed radiation treatment in 
sagittal, axial and coronal planes (Figure 4A–4C) and the 
dose volume histograms (DVHs) for all irradiated mice 
is shown (Figure 4D). These DVHs demonstrate that a 
highly uniform dose distribution across the tumor volume 
is achieved at the desired prescription dose of 8 Gy [20]. 
We determined the tumor growth delay using 
bioluminescence by calculating the time it takes for each 
Figure 2: effect of notcH inhibition combined with tMZ and rt on proliferation and clonogenicity in vitro. (A–b) 
Proliferation analysis of U87MG-Luc2 and E2 cells after indicated treatments. (c–d) Survival fraction of U87MG-Luc2 and E2 cells upon 
indicated treatments following radiation. Error bars indicate SEM.
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tumor to reach 10 × BLI signaling intensity from start 
of treatment (T10 × SI). A significant growth delay was 
observed in GSI-, 8 Gy- and TMZ-only treated groups 
(21.3 ± 2.9 days, 23.7 ± 2.6 days, and 37.1 ± 5.1 days, 
respectively) compared to the control group (16.4 ± 
0.9 days) (p < 0.01 for GSI- and 8 Gy- and TMZ-only 
groups) (Figure 5B). The median survival defined based on 
the weight loss, neurological signs and abnormal behavior 
as humane endpoints for the GSI- and 8 Gy- single 
treatments were not significantly different from the control 
(20.5 ± 4.5 days for GSI-only, 20 ± 8.4 days for 8 Gy-
only, 19 ± 3.0 days for control) (Figure 5C). Addition 
of GSI to either TMZ or 8Gy irradiation resulted in 
a significant growth delay (47.1 ± 4.5 days and 28.6 ± 
1.9 days, respectively) when compared with 8 Gy- or 
TMZ-only groups (p < 0.01) (Figure 5B). The median 
Figure 3: effect of notcH inhibition combined with tMZ and rt on 3d spheroid growth in vitro. (A) Schematic of 
the 3D spheroid assay treatment schedules. (b–e) Individual spheroid growth in U87 cells was imaged 3 × /week and the volume was 
calculated after indicated treatments till time to reach 20× starting volume. Spheroid growth demonstrates delays upon different treatment 
combinations compared with DMSO as vehicle control. Error bars indicates SEM. Asterisk indicates significance (*p < 0.05, **p < 0.01 
and ***p < 0.001, ns: not significant). 
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survival for these groups was significantly prolonged 
compared to control (33 ± 6.3 days for GSI + 8 Gy and 
44 ± 9.1 days for GSI + TMZ, p < 0.001 for both groups) 
(Figure 5C). Similarly, the standard of care treatment 
(8 Gy + TMZ) resulted in a significant growth delay (59.6 
± 3.8 days) when compared with 8 Gy- or TMZ-only 
groups (p < 0.01) as well as the TMZ + GSI group (p < 
0.01). The median survival for this group was significantly 
prolonged compared to single treatments (55 ± 5.7 days for 
8 Gy + TMZ, p < 0.001 comparing with 8 Gy- and TMZ-
only). The most profound growth delay (93.6 ± 18.4 days 
for 4 out of 5 mice, P < 0.01 compared with 8Gy + TMZ) 
and increase in median survival (81 ± 22.7 days for 4 out of 
5 mice, p < 0.001 compared with control and GSI + 8 Gy, 
p < 0.05 compared with GSI + TMZ and 8 Gy + TMZ) 
was observed in mice treated with triple combination of 
8 Gy, TMZ and GSI (Figure 5C). Addition of GSI to TMZ 
+ RT resulted in a highly significant synergistic effect 
(P < 0.0003). One out of 5 mice showed a cure defined as 
being tumor-free for > 14 weeks post start of treatment. 
Representative BLI and contrast-enhanced micro-CT 
images of a mouse in each treatment group at different 
time points post-treatment are shown (Supplementary 
Figure 4). We observed significant down regulation of 
HES1 and CD133 mRNA expression in tumors from GSI 
treated mice, compared to control treated mice (p = 0.01) 
(Figure 5D–5E). HEY2 mRNA was not altered upon GSI 
treatment (Supplementary Figure 5).
Figure 4: radiation treatment set-up and the resulting dose volume histograms. (A–c) Visualization of the tumor in the brain 
from different planes (Sagittal, Axial and coronal) and applied parallel-opposed radiation beams to target the tumor. (d) Resulting DVHs 
of the tumors after 8 Gy irradiation. Red line shows the average of the DVHs.
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No dose limiting toxicities were observed for single 
and double treatments although weight loss < 20% was 
invariably observed within the first or second week after 
treatment after which mice recovered (Supplementary 
Figure 6). Importantly, four out of nine mice receiving 
triple combination treatments were euthanized due to a 
significant weight loss prior to reaching endpoint despite 
very small histologically confirmed tumors. 
combination treatment (GsI + tMZ + rt) 
reduces the glioma stem cell population
To investigate the mechanism of increased radio- 
and chemo-sensitivity upon NOTCH inhibition, we 
evaluated the expression of the glioma stem cell marker 
CD133 using flow cytometry 4 days post-treatment in U87 
and E2 cells grown under adherent stem cell conditions 
(Figure 6A–6B). We observed a 4-fold increase in CD133 
expression in primary E2 and U87 cells upon single dose 
4 Gy RT. Pre-treatment with either GSI or TMZ reduced 
CD133 expression by 2.1 and 2.9 fold in primary E2 cells 
as well as 1.8 and 2 fold in U87 cells, respectively (Figure 
6A–6B). No significant differences were observed in TMZ 
+ GSI treated cells. Under the same treatment condition, 
SOX2 mRNA expression was significantly reduced upon 
GSI + RT and GSI + TMZ + RT treatments in both E2 
and U87 (Figure 6C–6D). Further, a strong reduction in 
SOX2 and Nestin protein expression in E2 and U87 cells, 
Figure 5: effect of notcH inhibition combined with tMZ and rt in orthotopic u87MG-luc2 glioblastoma in vivo. 
(A) Schematic of the treatment schedules in vivo. (b) Tumor growth delay upon indicated treatments measured by BLI signal intensity for 
mice in each treatment group and the end point was when the BLI signal intensity reached to 10× intensity of the starting treatment day. 
(c) Kaplan-meier survival curve indicates number of days mice survived post-treatment. End-point was assessed based on the neurological 
sign and weight loss. (d–e) mRNA expression of the HES1 and CD133 in tumor samples treated with GSI vs. control was determined 
by qRT-PCR. Values were normalized to Actin. Error bars indicates SEM. Asterisk indicates significance (*p < 0.05, **p < 0.01 and 
***p < 0.001, ns: not significant).
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respectively, were only observed in the triple combination 
(Figure 6E). GSI strongly inhibited NOTCH cleavage 
in E2 and U87 cells as shown by immunoblotting with 
Val1744 recognizing the active cleaved form of NOTCH1 
(NICD1) (Figure 6E). 
dIscussIon
Given the lack of a curative treatment for GBM, 
novel approaches are urgently needed in relevant in vitro 
and preclinical models that are predictive and mimic 
clinical routine to enable swift translation. Here, we show 
the therapeutic benefit of the addition of the clinically 
approved NOTCH/γ secretase inhibitor (RO4929097) 
combined with the standard of care in GBM: concurrent 
radiotherapy and chemotherapy with temozolomide. Our 
results show that in an orthotopic model for glioblastoma, 
NOTCH inhibition enhances radiotherapy, TMZ 
chemotherapy as well as a combination of both such that 
in 1 out of 5 mice tumor cure (defined as being tumor-free 
for >14 weeks) was achieved and in the remaining cohort 
a survival benefit of ~62 days and ~26 days was obtained 
Figure 6: effect of notcH inhibition combined with tMZ and rt on cd133, soX2 and nestin expression. (A–b) The 
expression of CD133 marker upon indicated treatments in U87MG-Luc2 and E2 cells was measured by flow cytometry. Graphs indicate 
the quantification of the relative CD133 expression normalized to IgG control upon indicated treatments. DAPI was used for the live cell 
staining. Concentration used in all cases was 10 µM GSI and 10 µM TMZ. (c–d) mRNA expression of the SOX2 stem cell marker in 
U87MG-Luc2 and E2 cells upon indicated treatments was measured by qRT-PCR. E) Protein expression of SOX2, Nestin and active form 
of NOTCH1 (NICD1) in E2 and U87 cells upon indicated treatments was analyzed by Western blotting. Actin and Lamin A/C serve as 
loading controls. Concentration used in all cases was 10 µM GSI and 10 µM TMZ. Error bars indicate SEM. Asterisk indicates significance 
(*p < 0.05, **p < 0.01 and ***p < 0.001, ns: not significant).
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when compared to the untreated mice or the standard of 
care treatment group (TMZ + RT), respectively.
Previously, we have shown the rationale for using 
the 3D spheroid system to model clinical efficacy of 
combination treatments [20]. Consistently, in this study we 
have shown that in vitro screening of NOTCH inhibitors 
combined with chemo-radiation (GSI + TMZ + RT) using 
3D spheroid system is a robust methodology to identify 
novel synergistic combination therapies for GBM that 
reflect in vivo response. The 3D model used here however 
still lacks important factors from the tumor micro-
environment that are known to contribute to response such 
as vasculature, fibroblasts or immune cells. Therefore, 
we used our previously established orthotopic GBM 
model [21] to address the in vivo efficacy of the NOTCH 
inhibitors combined with chemoradiation. Radiation-
induced necrosis of normal brain tissue is a dose-limiting 
factor in treatment of CNS tumors. Considering this 
and in contrast to standard devices using a single large 
beam, we used an image-guided small animal micro-
irradiator device that combines micro-CT imaging with 
conformal irradiation and millimeter-adjustable beams 
[20]. This was combined with treatment planning software 
(SmART–Plan) which made radiation treatment planning 
and delivery highly accurate. Similar to that in clinical 
practice, we determined dose-volume histograms (DVH) 
showing that the X-ray beams were highly conformal and 
localized to the tumor region, minimizing exposure to 
organs at risk such as the normal brain [20–22].
Based on our findings, growth responses between 
the in vitro spheroid and in vivo preclinical models did 
complement one another; however, there were some 
discrepancies as well. In accordance with the observation 
from other studies [16–17], we showed that NOTCH 
inhibition alone did not affect the spheroid growth in 
U87 cells but did result in a significant growth delay 
in vivo according to the BLI data. One explanation 
could be the contribution of NOTCH inhibition in the 
tumor microenvironment possibly by disrupting tumor 
angiogenesis [23] or blocking endothelial to tumor cell 
signaling [24–25], which was not addressed in this study. 
Our findings are in agreement with previous results 
showing the enhanced therapeutic effect of combined GSI 
with TMZ (in vitro and ex vivo) or GSI with RT (in vitro 
and in vivo) compared to each treatment alone [16, 24, 26]. 
While these findings are important to move NOTCH 
inhibitors forward as GBM therapeutics, contribution of 
GSI to current standard of care treatment (TMZ + RT) has 
never been reported to the best of our knowledge. In this 
study, for the first time we show that NOTCH inhibition 
in combination with TMZ + RT significantly enhances the 
3D spheroid growth delay in vitro and prolongs survival 
of the mice bearing the orthotopic glioma compared 
to TMZ + RT. This result is encouraging in developing 
new combination therapy for GBM; however, the clinical 
relevance of this study could further be maximized by the 
use of patient derived xenografts that may better reveal 
the gene expression profiles of the glioma patients and 
typical histological characteristics (micro-infiltrative, 
highly vascularized, palisading necrosis) compared to 
established glioma cell lines [27]. Recently, integrated 
genomic profiling of glioblastoma has led to new 
classifications with prognostic and predictive importance 
[28–31]. Targeted therapeutics against ‘actionable’ targets 
has however led to limited clinical efficacy in GBM 
[32]. This may in part be due to high heterogeneity in 
GBM and clonal expansion driven by treatment or de 
novo acquired resistance mechanisms [33]. Therapeutics 
targeting the survival of tumor initiating cells are more 
likely to be successful as they target “driver” populations. 
Identification of these driver populations needs further 
investigation but our work and that of others highlight 
the importance of glioma CSCs in growth and treatment 
response and their dependence on NOTCH signaling. 
We observed that NOTCH inhibition influenced 
the radiation-enhanced CD133 expression, in line with 
the expected role of NOTCH in the maintenance of 
glioma stem cells [24]. Importantly, it has been reported 
that endothelial cells can function as a stem cell niche to 
promote CD133 + self-renewal in glioblastoma [25] by 
providing NOTCH ligands that activate NOTCH receptors 
in CD133 + cells [24, 34]. If NOTCH inhibition also 
reduced CD133 + sub-populations directly or indirectly 
via endothelial cell signaling in vivo was not addressed in 
our study and requires further investigation. 
Our data showed that temozolomide was equally 
effective as single NOTCH inhibitor treatment or dual 
treatment in reducing radiation increase of CD133 + cells, 
consistent with other reports [35]. This finding could 
only be partly replicated in our clonogenics assays (not 
enriched for CD133 + ) suggesting that while CD133 + 
marks clonogenic cells, it does not reflect only glioma 
stem cells. Others report that CD133+ cells are resistant to 
chemotherapy [8, 36]. However, in some of these studies 
the viability of CD133+ cells was assessed only in short-
term culture using extremely high TMZ concentrations 
(0, 2–2 mM) and culture conditions not suited for the 
maintenance of the cancer stem cell phenotype [37–38]. 
In line with our data, TMZ treatment (5–25 uM) on glioma 
cells grown under stem cell enriched conditions reduced 
proliferation and survival at very low TMZ concentrations 
[39] and inhibited the growth of neurosphere in CD133+ 
sub-population and reduced tumorigenicity [35, 40]. While 
further investigation is needed to reconcile these findings, 
our data suggest that within the CD133+ population a 
treatment resistant clonogenic population exist sensitive 
to NOTCH inhibition which support this study and other 
studies showing that NOTCH inhibitors can sensitize to 
TMZ [16]. 
While the exact mechanism for the enhanced 
efficacy of the triple combination (GSI + RT + TMZ) 
treatment in vivo is not investigated, the marked reduction 
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in clonogenic survival upon triple combination treatment 
suggests an anti-glioma stem cell effect. Although 
triple treatment did not further reduce CD133+ surface 
population compared to dual treatments, it reduced SOX2 
expression a widely used marker for repopulating cells in 
context of radiation resistance [41–42] as well as Nestin 
another stem cell marker in glioma progression [43–44]. 
This suggests that the treatment resistant population 
sensitive to NOTCH inhibitors is contained within the 
CD133, SOX2 and Nestin overlap expression. The 
phenotypic and functional identity of this population 
in vivo would be a key step forward in understanding 
glioma treatment resistance [45].
Various clinical trials are underway to investigate 
whether NOTCH blockade using γ-secretase inhibitors 
improves cancer treatment [46]. However, one of the 
major challenges on the way is the untoward side 
effects associated with NOTCH inhibitors, especially 
the cytotoxicity in the gastrointestinal tract [47]. To 
maximize the therapeutic effects and minimize the 
systemic NOTCH-related side effects, improved dosage 
regimens have now been reported in phase 1 clinical 
trials that “spare“ the intestine [48]. In our study, using 
the same orally administrated GSI RO4929097 with 
similar scheduling (5 days on - 2 days off/ for 3 weeks), 
did not lead to irreversible weight loss or other toxic 
effects. However, we did observe deaths not due to the 
tumor burden but rather due to toxicity associated with 
the prescribed triple therapy regimen by a yet unknown 
mechanism. We speculate that this could be due to toxicity 
associated with the three-drug combinations. It is in our 
estimation that the TMZ component of the treatment was 
likely the cause of this toxicity, even though we used the 
lowest reported dosages found in the literature. In the 
future study, using a lower chemotherapy dose to cause 
a mild but significant growth delay could be a potential 
option to prevent toxicity from triple combinations. 
Furthermore, balancing efficacy and toxicity of 
γ-secretase inhibitors by optimizing treatment cycles 
and dosing schemes is paramount for successful future 
clinical applications. In this regard, a current clinical 
trial is recruiting patients to investigate the efficacy of 
RO4929097 in combination with radiation and TMZ 
(http:// ClinicalTrials.gov identifier NCT01119599). 
Importantly, both our in vitro and in vivo data indicate that 
the addition of GSI to either RT or TMZ may be equally 
effective as standard of care. This could be clinically 
significant in treatment of recurrent (TMZ resistant) 
tumors where RT and/or TMZ could be replaced with 
GSI. Taken together, we believe that our findings are 
promising for clinical translation to increase survival in 
GBM patients but that unanticipated toxicities may occur. 
Therefore, identification of a subset of patients who have 
active NOTCH signaling could predict the likelihood of 
increased response to anti-NOTCH therapy. More studies 
are needed to fully exploit the potent NOTCH inhibitors 
but also to recognize potential aggravating conditions that 
may occur.
MAterIAls And MetHods
cell line culture
U87MG-Luc2 (U87), primary E2 and G7 glioma 
cell lines were used in this study. E2 and G7 cells were 
derived from freshly resected human GBM specimens 
as previously described [49]. U87 cells were cultured in 
Hyclone MEM/EBSS (Fischer Scientific), 10% fetal calf 
serum, 1% L-Glutamine (Invitrogen), 1% non-essential 
amino acids (Invitrogen) and 1% sodium pyruvate 
(Invitrogen). E2 and G7 cells were cultured in MEMα 
(Gibco) supplemented with 5% L-glutamine. The U87 
cell identity was confirmed using the short tandem repeat 
(STR) analysis (Identicell, Denmark).
For western blotting and flow cytometry both cell 
lines were cultured in stem cell enriching conditions in 
Advanced DMEM F12 medium (Gibco) supplemented 
with 1% B27 (Invitrogen), 0.5% N2 (Invitrogen), 4 µg/ml 
heparin, 20 ng/ml fibroblast growth factor (bFGF, Sigma), 
20 ng/ml epidermal growth factor (EGF, Sigma) and 1% 
L-Glutamine. Stem cell enriched cultures were grown on 
Matrigel (BD Biosciences) coated flasks (1:50 dilution) in 
serum free media.
orthotopic brain tumor implantation and drug 
treatment
Immunocompromised CD1 nu/nu mice were used 
in this study. Animal work was performed in accordance 
with national guidelines. The procedure for tumor 
implantation has been described in detail previously 
[21]. After confirmation of tumor establishment, GSI was 
orally administered with a schedule of five days on and 
two days off for 3 weeks. One-week post-treatment GSI/
vehicle mice were irradiated. Directly after irradiation, 
mice were treated with TMZ/vehicle with a schedule of 
3 days on and 4 days off for 2 weeks. The control group 
received an intraperitoneal (i.p.) injection of 200 µl saline 
(TMZ-vehicle), and/or oral administration of 200 µl 
of 1.0% carboxymethyl cellulose with 0.2% Tween 80 
in sterile water (RO4929097-vehicle). The TMZ-only 
treated group received 30 mg/kg TMZ (Selleckchem) 
i.p. and oral RO4929097-vehicle, while the RO4929097 
treated group received 20 mg/kg RO4929097 orally and 
TMZ-vehicle i.p. RT-only group received 8 Gy single 
dose irradiation using the small animal micro-IR (X-RAD 
225Cx, Precision X-ray Inc., North Branford, CT). The 
combined treatment group was administered with the same 
concentration of TMZ i.p., RT and RO4929097 orally. 
RO4929097 (2,2-dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-
dibenzo (b,d) azeptin-7-yl)-N’-(2, 2, 3, 3, 3,-pentafluoro-
propyl)-malonamide) has been indicated as GSI in this 
study. The RO492909 was stored at 4°C. 
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In vivo imaging
Bioluminescent imaging (BLI) was performed 
using the Optix MX2 system (ART Inc., Saint-Laurent, 
QC). Animals were monitored 3×/week. Additionally, 
a selection of animals in each group were followed by 
contrast-enhanced micro-CT imaging using the small 
animal micro-IR (X-RAD 225Cx, Precision X-ray Inc., 
North Branford, CT). All the procedures for imaging and 
analysis have been extensively described previously [21]. 
In vivo irradiation: (smArt-Plan)
Radiotherapy dose was calculated and prescribed 
using the dedicated small animal radiotherapy planning 
system SmART-Plan (v1.3.1, Precision X-Ray, North 
Branford, CT), which has been previously validated [22]. 
Target delineation, treatment planning and irradiation 
was performed on anesthetized mice based on a 
contrast-enhanced micro-CT images that were shown 
to successfully visualize tumor boundaries as described 
previously [20, 21], and was completed while the animal 
remained anesthetized on the treatment bed. Within 
SmART-Plan the tumor was contoured and two 5-mm 
parallel-opposed beams were placed at the center of the 
tumor. This beam size ensured complete coverage plus 
a small margin for set-up uncertainties but still avoided 
irradiating most of normal brain tissue. Based on earlier 
work, a homogeneous dose of 8 Gy was prescribed to the 
target with each beam contributing an equal amount of 
dose. The source-to-axis distance was 30 cm. Radiation 
was delivered using the small animal irradiator at 225kVp, 
12 mA (filtration of 0.3mm of copper) which provides a 
dose rate of approximately 3 Gy/minute. 
3d spheroid assay
96-well plates were coated with 50µl of autoclaved 
1.5% agarose in serum free medium [50]. 2800 U87 and 
5000 G7 cells in 200 μl complete medium were seeded 
on the agarose coated plates per well. One spheroid per 
well was formed within 4 days after seeding. For each 
condition, at least 12 spheroids were tested. 4 days 
post-seeding first phase-contrast pictures were taken 
from all the spheroids individually and then the sphere 
volume was analyzed using an in-housed script using 
Matlab program (Mathworks, 2009b, CT) and available 
for download [51]. Directly after image acquisition, 
treatment regimens were administered. GSI (RO4929097) 
and TMZ were administered immediately after irradiation 
in RT treated groups. The control group received only 
DMSO. Final concentration for GSI-only and TMZ-only 
treated group was 10 µM and 5 µM, respectively for U87 
cells and 20 µM and 5 µM, respectively for G7 cells. The 
RT-only group was irradiated with a single dose of 4 Gy. 
All the combination groups were treated with the same 
doses. So as not to disrupt the sphere structure, in all 
treatment groups 100 μl of medium was discarded very 
carefully and 100 μl of the 2× treatment pre-mixtures 
were added. The drugs were washed out by refreshing 
the medium 3×/week. TMZ was washed out after three 
days incubation in the first week and the same treatment 
procedure was repeated in the second week, while GSI 
was refreshed twice weekly for two weeks. TMZ was 
diluted in DMSO and stored in 100 mM stock at −80°. 
GSI was diluted in DMSO and stored in 10 mM stock 
at −20°. Sphere volumes were measured 3 times a week 
and experiments were terminated when treated spheres 
reached 20× treatment volume. 
Proliferation 
500 cells/well (U87) or 2000 cells/well (E2) were 
seeded in 96 well plates and were treated 24 h post-
seeding with 5 µM TMZ and/or 10 uM GSI (RO4929097) 
and/or single dose of 4 Gy RT (Philips X-ray tube; 225 kV; 
10 mA). The three treatments were tested as single, double 
and triple combinations with 6 replicates per condition. 
72 h post-treatment TMZ was washed out and GSI was 
refreshed. Cell confluency was monitored every 2 h using 
the phase-contrast mode of the IncuCyte ™ FLR (2011A) 
live-imager. TMZ was diluted in DMSO and stored in 
100 mM stock at −80°. GSI was diluted in DMSO and 
stored in 10 mM stock at −20°.
Quantitative real time Pcr (qPcr)
RNA extraction was performed using the 
NucleoSpin RNA II kit (Bioke). cDNA was prepared using 
the iScript cDNA Synthesis kit (BioRad). Reactions were 
carried out in a 10 μl volume using sensiMix SYBR low-
ROX kit (GC Biotech) with the ABI Prism 7500 Sequence 
Detection System. Values for each gene were normalized 
to expression levels of Actin RNA. Primer sequences have 
been described previously [52].
clonogenic survival assay
Cells were seeded in 6-cm dishes to be 70% 
confluent at the time of irradiation. Cells were irradiated 
with 2 Gy, 4 Gy or 6 Gy and non-treated (Philips X-ray 
tube; MU15F/225, 225 kV; 10 mA). Directly after 
irradiation, cells were trypsinized and seeded at densities of 
250 or 1000 cells per well for E2 and 500 cells per well for 
U87 in triplicate in 6-well plates and allowed to adhere for 
4 h in complete medium. Then, the medium was replaced 
with treated medium: DMSO in control group, 10 µM 
TMZ for E2 cells and 5 µM TMZ for U87 cells for 48 h 
in TMZ-only treated group and 10 µM RO4929097 in 
GSI-only treated group. The combination groups were also 
treated with the same concentrations. RO4929097 was 
refreshed every 5 days during the experiment. Colonies 
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were counted manually after 2 weeks. The minimum 
number of cells per colony was 30. 
Flow cytometry
Cells were first irradiated with 4 Gy and then treated 
with 10 µM RO4929097 and 10 µM TMZ as well as their 
combination. Cultures were disaggregated with accutase 
4 days post-treatment, cells were washed with PBS once 
and incubated with CD133/2-PE (1:200; Miltenyi Biotech) 
or isotype control antibody on ice for 30 min. Then cells 
were washed with PBS 2×, resuspended in 200 µl PBS and 
fixed in 1% paraformaldehyde. Just before measurements 
of each FACS tube DAPI (final concentration 3 µM) was 
resuspended in each tube. FACS analysis was carried out 
on FACS Calibur machine (BD Biosciences). 
Western blotting
Cells were first irradiated with 4 Gy and then treated 
with 10 µM RO4929097, 10 µM TMZ as well as their 
combination. 4 days post-treatment total cell lysate was 
prepared using SDS lysis buffer. Lysates were blotted onto a 
PVDF-membrane. Membranes were probed overnight at 4°C 
with primary antibodies and bound antibodies were visualized 
using HRP-linked secondary antibodies (Cell-Signaling) and 
ECL Luminescence (Pierce Biotechnology). Anti-SOX2 
(ab75485, Abcam), anti-Nestin (ab6320, Abcam), anti-beta-
tubulin III (T3952, Sigma-Aldrich), and anti-Lamin A/C 
(Sigma-Aldrich) were used at 1:1000 dilution. 
statistical analysis
Statistical analysis was performed using GraphPad 
Prism Software (v5.02, San Diego, CA). For all measured 
quantities mean ± SEM are reported except where stated. 
For survival data median ± SD is reported. For tumor 
growth delay mean ± SD is reported. Mann-Whitney or 
ANOVA tests were used to analyze differences in growth 
delay and in clonogenic survival. We used a two-way 
ANOVA to test the interaction (synergism) between GSI 
and TMZ + RT. The log-rank (Mantel-Cox) test was used 
to compare the survival curves. A p-value smaller than 
0.05 was considered statistically significant.
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